自膨式颅内药物洗脱支架系统用于症状性颅内动脉粥样硬化性狭窄患者:初步经验与中期血管造影随访
这项前瞻性研究纳入16例狭窄≥70%的症状性颅内动脉粥样硬化性狭窄患者,置入16枚COMETIU自膨式药物洗脱支架,器械成功率和技术成功率均为100%,围手术期无卒中或死亡,术后至少6个月血管造影随访未发现支架内再狭窄,作者认为COMETIU治疗ICAS安全有效。
要点
- 16例狭窄≥70%的ICAS患者置入COMETIU支架,器械与技术成功率均为100%。
- 围手术期无卒中或死亡,术后至少6个月造影随访无支架内再狭窄。
- 随访期内无缺血性或出血性卒中报告。
核心结论
- COMETIU用于治疗ICAS安全有效,术中风险低,中期随访支架内再狭窄率低。
研究设计与样本
- 前瞻性研究,纳入2022年9月4日至2023年2月1日期间接受血管内治疗的16例ICAS(狭窄≥70%)患者,置入16枚COMETIU自膨式药物洗脱支架(Sinomed Neurovita Technology Inc.,中国),主要结局为术后6个月支架内再狭窄发生率。
诊断标准与关键数值
- 纳入标准为症状性颅内动脉粥样硬化性狭窄且狭窄程度≥70%;主要结局指标为术后6个月支架内再狭窄发生率;次要疗效指标为器械成功率和手术技术成功率,均为100%;次要安全指标包括术后30天内卒中或死亡、31天至6个月及1年靶血管供血区复发性缺血性卒中的年累积发生率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Symptomatic intracranial atherosclerotic stenosis (ICAS) is a major cause of ischemic stroke worldwide. In patients undergoing endovascular treatment for ICAS, in-stent restenosis (ISR) is associated with ischemic stroke recurrence.
OBJECTIVE: Intracranial drug-eluting self-expanding stent systems (COMETIU; Sinomed Neurovita Technology Inc., CHN) are new devices for treating ICAS. This study evaluated the perioperative experience and medium-term outcomes of COMETIU in 16 patients.
METHODS: We prospectively analyzed 16 patients with ICAS (≥ 70% stenosis) who underwent intravascular therapy between September 4, 2022, and February 1, 2023. The primary outcome was the incidence of ISR at 6 months postoperatively. The secondary efficacy outcomes were device and technical success rates. The secondary safety outcomes included stroke or death within 30 days after the procedure and the cumulative annual rate of recurrent ischemic stroke in the target-vessel territory from 31 days to 6 months and 1 year.
RESULTS: A total of 16 patients with 16 intracranial atherosclerotic lesions were treated with 16 COMETIUs. All procedures were performed under general anesthesia with 100% device and technical success rates, with no cases of periprocedural stroke or death. The mean radiographic follow-up duration was at least 6 months postoperatively, and all patients presented for radiographic and clinical follow-up. There were no reported ischemic or hemorrhagic strokes. Angiographic follow-up for all patients revealed no cases of ISR.
CONCLUSION: COMETIU is safe and effective for treating ICAS, with minimal risk during the procedure and a low rate of ISR during medium-term follow-up.
引用
- Zhang F, Yao J, Wu P, et al. Self-expanding intracranial drug-eluting stent system in patients with symptomatic intracranial atherosclerotic stenosis: initial experience and midterm angiographic follow-up. Neuroradiology. 2024. PMID: 38977434. doi:10.1007/s00234-024-03423-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。